author-photo

Verna L. Welch

Pfizer

27

Papers

27

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)

2021 Journal of Cancer Research and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis.

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (0)
A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

2021 Hematology, Transfusion and Cell Therapy
Show All
- Source
- Cite
- Save
Citations (0)
A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.

2020 PharmacoEconomics
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (3)
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (5)
Practice Mapping in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL): The Use of Measurable Residual Disease (MRD) Assessment in Real-World U.S. Community Oncology Practice

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)